Summary

Eligibility
for people ages 18-50 (full criteria)
Location
at Oakland, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).

Official Title

A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

Details

This is a Phase 1/2 single-arm, open-label, multicenter study evaluating the safety and efficacy of a single unit dose of EDIT-301 for autologous hematopoietic stem cell transplant (HSCT) in subjects with severe SCD. Planned study subjects will be comprised of male and female adult subjects with severe SCD, from 18 to 50 years of age, inclusive.

Keywords

Sickle Cell Disease Hemoglobinopathies Anemia Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Genetic Diseases, Inborn Cell Disorders, Sickle HbS Disease Sickling Disorder Due to Hemoglobin S Hematologic Diseases EDIT-301

Eligibility

You can join if…

Open to people ages 18-50

Diagnosis of severe sickle cell disease as defined by:

  • Documented severe SCD genotype (βS/βS, βS/β0, or βS/β+)
  • History of at least two severe vaso-occlusive crisis events per year requiring medical attention despite hydroxyurea or other supportive care measures in the two year-period prior to provision of informed consent

Karnofsky Performance Status ≥ 80

You CAN'T join if...

  • Available 10/10 HLA-matched related donor
  • Prior HSCT or contraindications to autologous HSCT
  • Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients
  • Unable to receive red blood cell (RBC) transfusion for any reason
  • Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine
  • Any history of severe cerebral vasculopathy
  • Inadequate end organ function
  • Advanced liver disease
  • Any prior or current malignancy or immunodeficiency disorder
  • Immediate family member with a known or suspected Familial Cancer Syndrome
  • Clinically significant and active bacterial, viral, fungal, or parasitic infection

Locations

  • UCSF Benioff Children's Hospital accepting new patients
    Oakland California 94609 United States
  • Children's Hospital Colorado accepting new patients
    Aurora Colorado 80045 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Editas Medicine, Inc.
ID
NCT04853576
Phase
Phase 1/2
Study Type
Interventional
Last Updated